September 23, 2022 10:48 AM EDT
News Briefing

Pfiz­er and Sang­amo re-open PhI­II of he­mo­phil­ia A gene ther­a­py; AEON head­ed to PhI­II

Kyle LaHucik

Senior Reporter

A year af­ter vol­un­tar­i­ly paus­ing the Phase III study of their he­mo­phil­ia A gene ther­a­py pro­gram, and four months af­ter FDA lift­ed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

Bridge­Bio’s At­tru­by out­per­forms sales ex­pec­ta­tions, shares rise

GSK's sup­ply chain 're­set' af­ter Ha­le­on spin­off to ease tar­iff im­pact, CEO says

Ar­tios drug ex­ploits ‘repli­ca­tion stress’ in can­cer, shrink­ing sub­set of tu­mors in ear­ly study

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times